| Literature DB >> 27951626 |
Şefika Elmas Bozdemir1, Yasemin Ay Altıntop2, Salih Uytun1, Humeyra Aslaner1, Yasemin Altuner Torun1.
Abstract
BACKGROUND/AIMS: Brucellosis patients present various non-specific clinical symptoms, such as fever, fatigue, sweating, joint pain, arthritis, myalgia, and headache. Based on the nonspecifity of its clinical signs and symtoms, we decided to evaluate whether mean platelet volume (MPV) , neutrophil to lymphocyte ratio (NLR), and platelet to lymphocyte ratio (PLR) will contribute to the diagnosis.Entities:
Keywords: Brucellosis; Child; Diagnosis; Mean platelet volume; Neutrophil to lymphocyte ratio
Mesh:
Year: 2016 PMID: 27951626 PMCID: PMC5668393 DOI: 10.3904/kjim.2016.092
Source DB: PubMed Journal: Korean J Intern Med ISSN: 1226-3303 Impact factor: 2.884
Demographic and clinical characteristics of the 60 patients
| Characteristic | Value |
|---|---|
| Age, mon | 30 (1–204) |
| Male sex | 49 (81.7) |
| Symptoms and clinical signs | |
| Fever | 60 (100) |
| Arthralgia | 56 (93.3) |
| Weakness | 54 (90.0) |
| Myalgia | 50 (83.3) |
| Anorexia | 34 (56.7) |
| Sweating | 27 (45.0) |
| Arthritis | 17 (28.3) |
| Peripheral lymphadenopathy | 10 (16.7) |
| Abdominal pain | 8 (13.3) |
| Hepatosplenomegaly | 7 (11.7) |
| Splenomegaly | 1 (1.7) |
| Serum agglutination test results | |
| 1/20[ | 1 (1.7) |
| 1/160 | 30 (50.0) |
| 1/320 | 14 (23.4) |
| 1/640 | 8 (13.3) |
| 1/1,280 | 7 (11.7) |
| Erythrocyte sedimentation rate, mm/hr | 9.5 (2–56) |
| C-reactive protein, mg/dL | 8.9 (3.17–252) |
| Treatment | |
| Rifampicin + doxycycline | 22 (36.7) |
| Rifampicin + doxycycline + gentamicin | 15 (25.0) |
| Rifampicin + TMP-SMT | 13 (21.7) |
| Rifampicin + TMP-SMT + gentamicin | 8 (13.3) |
| Rifampicin + TMP-SMT + cefotaxime/ceftriaxone[ | 2 (3.3) |
Values are presented as median (range) or number (%).
TMP-SXT, trimethoprim-sulfamethoxazole.
Case with congenital infection.
One case with relapsing disease and one case with congenital infection.
Comparison of the laboratory findings of patient and control groups
| Variable | Patient (n = 60) | Control (n = 55) | |
|---|---|---|---|
| WBC, /mm3 | 6,870 (1,220–18,370) | 6,500 (3,590–10,770) | 0.186 |
| Neutrophil, /mm3 | 2,820 (620–15,690) | 2,790 (890–4,850) | 0.103 |
| Lymphocyte, /mm3 | 3,020 (270–6,930) | 3,100 (1,520–5,840) | 0.223 |
| NLR | 0.99 (0.31–10.2) | 0.89 (0.17–1.39) | 0.032 |
| PLR | 95.2 (22.2–370) | 93.1 (1.4–172) | 0.853 |
| Hemoglobin, g/dL | 12.6 ± 2.0 | 13.4 ± 1.4 | 0.017 |
| Platelet, /mm3 | 272,366 ± 91,913 | 309,963 ± 73,000 | 0.017 |
| MPV, fL | 8.9 ± 1.14 | 9.3 ± 0.76 | 0.049 |
| ESR, mm/hr | 9.5 (2–56) | 2.5 (2–10) | < 0.001 |
| CRP, mg/dL | 8.93 (3.17–252) | 3.28 (3.17–5.04) | < 0.001 |
Values are presented as median (range) or mean ± SD.
WBC, white blood cell; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; MPV, mean platelet volume; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein.
Comparison of the laboratory findings of artritis positive, arthritis negative patients, and control group
| Variable | Arthritis (+) | Arthritis (–) | Control | |
|---|---|---|---|---|
| WBC, /mm3 | 6,850 (3,590–13,710) | 6,890 (1,220–18,370) | 6,500 (3,590–10,770) | 0.310 |
| Neutrophil, /mm3 | 3,540 (950–10,570)[ | 2,780 (620–15,690)[ | 2,790 (890–4,850)[ | 0.007 |
| Lymphocyte, /mm3 | 2,710 (1,450–5,650) | 3,050 (270–6,930) | 3,100 (1,520–5,840) | 0.405 |
| NLR | 1.38 (0.37–5.9)[ | 0.95 (0.31–10.2)[ | 0.90 (0.17–1.3)[ | 0.002 |
| PLR | 92.4 (22.2–214) | 99.1 (46.5–370) | 93.0 (1.4–172) | 0.944 |
| Hemoglobin, g/dL | 12.8 ± 1.7 | 12.6 ± 2.1 | 13.4 ± 1.43 | 0.059 |
| Platelet, /mm3 | 251,823 ± 72,550[ | 280,488 ± 98,102[ | 309,963 ± 73,003[ | 0.035 |
| MPV, fL | 9.3 ± 1.08[ | 8.8 ± 1.14[ | 9.3 ± 0.76[ | 0.034 |
Values are presented as median (range) or mean ± SD.
WBC, white blood cell; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; MPV, mean platelet volume.
Indicates the difference.
Indicates the similarity.